Study of IMM-H014 for fatty liver disease (MASH)
Treatments studied
Part of Digestive system clinical trials.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have fatty liver disease (MASH) with at least 10% liver fat on a special MRI scan.
- You must have at least one of these: high blood pressure, diabetes, high cholesterol, or being overweight (BMI 24 or higher).
- Your liver enzyme (ALT) must be above the normal level, or you must have a liver biopsy in the past 6 months showing MASH.
- You must not have cirrhosis (advanced liver scarring), severe alcohol use, or uncontrolled diabetes (HbA1c 8% or higher).
- You must be willing to avoid certain foods (like grapefruit) and alcohol during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This trial tests an experimental gene therapy (VV-14303) given as a single injection into the muscle to treat MASH, a common type of fatty liver disease with inflammation. The study will check if the treatment is safe and helps improve liver health.
This trial tests a new drug called IMM-H014 in healthy volunteers to see if it is safe and how the body processes it. It also checks if food changes how the drug works. You may join if you are generally healthy and meet the age and weight requirements.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.